Continued Treatment and Maintenance Therapy

According to the FDA, continued treatment in AML is an extended course of treatment after induction therapy with the objective of controlling disease burden. Treatment may be time-limited, but is generally given until unacceptable toxicity or relapse. Maintenance therapy is an extended but time-limited course of treatment given after a patient has achieved CR with the objective of reducing the risk of relapse beyond the period of treatment.

Reference: 1. Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment. FDA website. August 2020. Accessed June 11, 2021.